Keating MJ - Search Results

1

Phase II study of alemtuzumab in chronic lymphoproliferative disorders.

Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Ferrajoli A, et al. Among authors: keating mj. Cancer. 2003 Aug 15;98(4):773-8. doi: 10.1002/cncr.11551. Cancer. 2003. PMID: 12910522 Free article. Clinical Trial.

2

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).

Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, et al. Estey EH, et al. Among authors: keating mj. Blood. 1992 Feb 15;79(4):882-7. Blood. 1992. PMID: 1346577 Free article.

3

Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia.

del Giglio A, O'Brien S, Ford R, Saya H, Manning J, Keating M, Johnston D, Khetan R, el-Naggar A, Deisseroth A. del Giglio A, et al. Blood. 1992 May 15;79(10):2717-20. Blood. 1992. PMID: 1350226 Free article.

4

Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone.

Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Anaissie E, et al. Ann Intern Med. 1992 Sep 15;117(6):466-9. doi: 10.7326/0003-4819-117-6-466. Ann Intern Med. 1992. PMID: 1354425

5

New drugs in the treatment of chronic lymphocytic leukemia.

Keating MJ, O'Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. Keating MJ, et al. Leukemia. 1992 Nov;6 Suppl 4:140-1. Leukemia. 1992. PMID: 1359203 No abstract available.

6

Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.

Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W. Kemena A, et al. Cancer Chemother Pharmacol. 1992;31(3):193-9. doi: 10.1007/BF00685547. Cancer Chemother Pharmacol. 1992. PMID: 1464155 Free article.

7

Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.

Kantarjian HM, Smith T, Estey E, Polyzos A, O'Brien S, Pierce S, Beran M, Feldman E, Keating MJ. Kantarjian HM, et al. Among authors: keating mj. Am J Med. 1992 Dec;93(6):599-604. doi: 10.1016/0002-9343(92)90191-d. Am J Med. 1992. PMID: 1466355

8

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.

Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Kantarjian HM, et al. Among authors: keating mj. J Clin Oncol. 1992 May;10(5):772-8. doi: 10.1200/JCO.1992.10.5.772. J Clin Oncol. 1992. PMID: 1569449

9

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

10

Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.

Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Keating MJ, et al. Leukemia. 1992;6 Suppl 2:78-80. Leukemia. 1992. PMID: 1578950 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

912 results

Search Page

Filters